Form 4: HilleVax Director Jeryl Hilleman Receives Significant Equity Grant

HilleVax, Inc. Director Jeryl L. Hilleman was granted 17,199 Restricted Stock Units (RSUs) as part of the company's non-employee director compensation program.

Summary

• Jeryl L. Hilleman, a Director of HilleVax, Inc. (HLVX), acquired 17,199 shares of Common Stock on June 23, 2025.
• These shares were granted as Restricted Stock Units (RSUs) under the Registrant's Non-Employee Director Compensation Program.
• The RSUs were granted at a price of $0 per unit.
• Following this transaction, Jeryl L. Hilleman beneficially owns a total of 59,224 shares of Common Stock.
• The RSUs will vest 100% on the first anniversary of the grant date (June 23, 2026) or upon a Change in Control, subject to continued service on the board.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders, but does not indicate significant new positive or negative developments for the company's operations or financial health.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Jeryl L. Hilleman aligns the director's interests with long-term shareholder value.
• The compensation structure encourages continued service on the board through vesting conditions.

Negatives

• The issuance of new Restricted Stock Units (RSUs) could lead to minor future dilution for existing shareholders upon vesting.

Risks

• Vesting of the RSUs is contingent on the non-employee director continuing in service on the Registrant's board of directors through the vesting date.

Future Outlook

The 17,199 Restricted Stock Units granted to Director Jeryl L. Hilleman are set to vest 100% on the first anniversary of the grant date (June 23, 2026) or earlier upon a Change in Control, provided the director continues in service.

Industry Context

This is a routine insider transaction filing (Form 4) for director compensation, common across publicly traded companies, and does not provide specific industry-wide insights or trends.

Comparison to Industry Standards

• Director compensation through equity grants like Restricted Stock Units (RSUs) is a standard practice in the biotechnology and pharmaceutical industries, similar to companies such as Moderna, Pfizer, or BioNTech, aiming to align director incentives with long-term company performance and shareholder interests.
• The specific number of units granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The grant of 17,199 Restricted Stock Units to Jeryl L. Hilleman, a director, constitutes a related party transaction as part of the company's non-employee director compensation program.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon RSU vesting, but also improved alignment of director incentives with long-term shareholder value.

Next Steps

• Continued service of Jeryl L. Hilleman on the HilleVax, Inc. board of directors.
• Vesting of 17,199 Restricted Stock Units on June 23, 2026, or earlier upon a Change in Control.

Key Dates

Keywords

HilleVax, HLVX, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Jeryl Hilleman